Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 5Biliary Tract Neoplasms 4Colonic Neoplasms 3Sarcoma 2Rectal Neoplasms 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Uterine Cervical Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Rare Tumour 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dermatofibrosarcoma 1

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2envafolimab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Refractory Solid Tumors × envafolimab × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡